ClinicalTrials.Veeva

Menu

A Pan-European Study on Minimally Invasive Versus Open Pancreatoduodenectomy in High-volume Centers (MI-PD)

S

S (Sjors) Klompmaker, MD

Status

Completed

Conditions

Pancreas Cancer
Pancreas Cyst
Pancreatic Neoplasms

Treatments

Procedure: Open pancreatoduodenectomy
Procedure: Minimally invasive pancreatoduodenectomy

Study type

Observational

Funder types

Other

Identifiers

NCT03172572
W16_401#17.011

Details and patient eligibility

About

RATIONALE: Minimally-invasive pancreatoduodenectomy (MIPD), either laparoscopic or robot-assisted, has been suggested as a valuable alternative to open pancreatoduodenectomy (OPD). The generalizability of the current literature is, however, unknown since randomized studies are lacking, and current data are published from few, very high volume centers and selection bias with a lack of case-matched series. International studies are lacking completely.

OBJECTIVE: To compare outcomes of MIPD versus open pancreatoduodenectomy (OPD), in high-volume European pancreas centers (>10 MIPDs per year, total >20 PDs per year).

METHODS: A retrospective multicenter propensity-score matched cohort study including all consecutive patients who underwent MIPD (or MI total pancreatectomy) between January 2012 and December 2016, for pancreatic head, bile duct, or duodenal cancer or cysts except chronic pancreatitis. Predefined electronic case report forms will be disseminated amongst participating centers. Participants are responsible for their own data collection. Matching of MIPD cases (collected from participating centers) to OPD controls (extracted from Dutch and German national registries) will be based on propensity scores determined by logistic regression including preoperative variables: year of surgery, demographics, BMI, ASA, comorbidities, tumor size, tumor etiology (diagnosis), and multivisceral resection. Primary outcome is 90-day major morbidity(Clavien-Dindo ≥ 3a). Secondary outcomes are 90-day postoperative events including: pancreatic fistula, length of hospital stay, R0 (microscopically negative) resection margin, malignant lymph node ratio, days to adjuvant therapy and overall survival.

Enrollment

4,220 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Indication for open or minimally invasive pancreatoduodenectomy
  • Pancreatic head, bile duct, or duodenal cancer or cysts

Exclusion criteria

  • Chronic pancreatitis without suspected solid tumor.

Trial design

4,220 participants in 1 patient group

Indication for surgery
Description:
Solid neoplasms
Treatment:
Procedure: Open pancreatoduodenectomy
Procedure: Minimally invasive pancreatoduodenectomy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems